[Initial clinical studies of the preparation Immucyst for immunotherapy in patients with carcinoma in situ (CIS) of the bladder].

Abstract

Over a 12-month period, thirteen patients, 10 men and 3 women, with recurrent surface transitional cell carcinomas of the urinary bladder in conjunction with CIS, are picked out and subjected to treatment. Distribution of the patients: primary multiple carcinomas combined with CIS, Ta-T1/G1-G2-4 cases; recurrent multiple carcinomas, with CIS, Ta-T1/G2-two, recurrent multiple carcinomas, combined with CIS, Ta-T1/G2-five, and T1/G3-two cases. In all instances transurethral resection (TUR) of both visible carcinomas, and CIS areas, is performed. Induction Immucyst therapy is carried out according to protocol: 3 vials BCG vaccine, dissolved in 50 ml serum, inserted intravesically once weekly over 6 weeks. The fluid is retained by the patients for up to 2 hours. Therapy is commenced within 7-14 days after TUR. Cystoscopy, cytology and biopsy of suspected areas ar done at 3, 6 and 12 days. Six of the patients reported on undergo 12-month follow-up study. The remainder (6 cases) are followed up for periods ranging from 3 to 6 months. At the actual stage of study, twelve patients are free of recurrences, and present negative cytological findings. One patient alone with carcinoma stage T1/G3 develops recurrence, treated with TUR and laser coagulation followed by immunotherapy. Two thirds of the patients sustain transitory pollakiuria and dysuria, and one third-subfebrile temperature persisting for 48 hours.

• Authors: I Ormanov, Kh Kumanov, P Panchev, S Kirilov, A Filev, K Ianev, D Maki
• Journal: Khirurgiia (Khirurgiia (Sofiia)) Vol. 47 Issue 3 Pg. 11-2 ( 1994) ISSN: 0450-2167 [Print] Bulgaria
• Vernacular Title: Nachalni klinichni prouchvaniia na preparata Immucyst za imunoterapiia pri bolni s kartsinom in situ (CIS) na pikochniia mekhur.
• PMID: 8531421 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• BCG Connaught
• BCG Vaccine

Topics

• Adult
• Aged
• BCG Vaccine (adverse effects, therapeutic use)
• Carcinoma in Situ (therapy)
• Carcinoma, Transitional Cell (therapy)
• Female
• Follow-Up Studies
• Humans
• Immunotherapy (adverse effects, methods)
• Male
• Middle Aged
• Neoplasm Recurrence, Local (therapy)
• Urinary Bladder Neoplasms (therapy)